SMP0127865
View Pathway
|
1D09C3 Drug Metabolism
|
Metabolic
|
|
|
SMP0130777
View Pathway
|
2,2'-Dibenzothiazyl disulfide Drug Metabolism
2,2'-Dibenzothiazyl disulfide is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. 2,2'-Dibenzothiazyl disulfide passes through the liver and is then excreted from the body mainly through the kidney.
|
Metabolic
|
- 2,2'-Dibenzothiazyl disulfide
|
|
SMP0145129
View Pathway
|
2,2'-Dibenzothiazyl disulfide Drug Metabolism Action Pathway
|
Drug Action
|
- 2,2'-Dibenzothiazyl disulfide
|
|
SMP0121131
View Pathway
|
2-Amino-3-Carboxymuconate Semialdehyde Degradation
This pathway is part of a major route of the degradation of L-tryptophan. It begins with 2-amino-3-carboxymuconate-6-semialdehyde which is generated from L-tryptophan degradation. The 2-amino-3-carboxymuconate-6-semialdehyde first is acted upon by a decarboxylase, forming 2-aminomuconic acid semialdehyde, which is then dehydrogenated by 2-aminomuconic semialdehyde dehydrogenase to form 2-aminomuconic acid. An unknown protein forms a 2-aminomuconate deaminase which forms (3E)-2-oxohex-3-enedioate, and a second unknown protein forms a 2-aminomuconate reductase, which forms oxoadipic acid from (3E)-2-oxohex-3-enedioate. Finally, within the mitochondria, oxoadipic acid is dehydrogenated and a coenzyme A is attached by the organelle’s oxoglutarate dehydrogenase complex, forming glutaryl-CoA. Glutaryl-CoA can then be further degraded.
|
Metabolic
|
|
|
SMP0125703
View Pathway
|
2-Aminoadipic 2-Oxoadipic Aciduria
2-Aminoadipic 2-oxoadipic aciduria is a disorder of lysine metabolism caused by a defective DHTKD1 gene. DHTKD1 is predicted to code for a component of a supercomplex similar to the 2-oxoglutarate dehydrogenase complex (OGDHc) which catalyzes the conversion of 2-oxoadipate into glutaryl-CoA. This disease is characterized by a large accumulation of 2-oxoadipate and 2-hydroxyadipate in the urine. Symptoms of the disease include mild to severe intellectual disability, developmental delay, ataxia, muscular hypotonia, and epilepsy. However, most cases are asymptomatic.
|
Disease
|
|
|
SMP0000719
View Pathway
|
2-Aminoadipic 2-Oxoadipic Aciduria
2-Aminoadipic 2-oxoadipic aciduria is a disorder of lysine metabolism caused by a defective DHTKD1 gene. DHTKD1 is predicted to code for a component of a supercomplex similar to the 2-oxoglutarate dehydrogenase complex (OGDHc) which catalyzes the conversion of 2-oxoadipate into glutaryl-CoA. This disease is characterized by a large accumulation of 2-oxoadipate and 2-hydroxyadipate in the urine. Symptoms of the disease include mild to severe intellectual disability, developmental delay, ataxia, muscular hypotonia, and epilepsy. However, most cases are asymptomatic.
|
Disease
|
|
|
SMP0000136
View Pathway
|
2-Hydroxyglutric Aciduria (D and L Form)
L-2-Hydroxyglutaric Aciduria (D-2-Hydroxyglutaric Aciduria ) is an autosomal recessive disease caused by a mutation in the L2HGDH gene which codes for L-2-Hydroxygluarate dehydrogenase. A deficiency in this enzyme results in accumulation of L-2-Hydroxyglutaric acid in plasma, spinal fluid, and urine; and L-lysine in plasma and spinal fluid. Symptoms, which present at birth, include ataxia, hypotonia, mental retardation, and seizures. Premature death often results. D-2-Hydroxyglutaric Aciduria is an autosomal recessive disease caused by a mutation in the D2HGDH gene which does for D-2-Hydroxygluarate dehydrogenase. A deficiency in this enzyme results in accumulation of D-2-Hydroxyglutaric acid in plasma, spinal fluid, and urine; oxoglutaric acid in urine; and gabba-aminobutyric acid in spinal fluid. Symptoms, which present at birth, include ataxia, hypotonia, mental retardation, and seizures. Premature death often results.
|
Disease
|
|
|
SMP0000549
View Pathway
|
2-Ketoglutarate Dehydrogenase Complex Deficiency
2-Ketoglutarate dehydrogenase complex deficiency, also known as alpha-ketoglutarate dehydrogenase deficiency or oxoglutaric aciduria, is an autosomal recessive disorder of the Krebs cycle caused by a defective oxoglutarate dehydrogenase complex (OGDC). OGDC catalyzes the conversion of 2-ketoglutarate into succinyl-CoA. This disorder is characterized by a large accumulation of 2-ketoglutarate in the urine. Symptoms of the disorder include opisthotonus, ataxia, developmental delay, and seizures.
|
Disease
|
|
|
SMP0125755
View Pathway
|
2-Ketoglutarate Dehydrogenase Complex Deficiency
2-Ketoglutarate dehydrogenase complex deficiency, also known as alpha-ketoglutarate dehydrogenase deficiency or oxoglutaric aciduria, is an autosomal recessive disorder of the Krebs cycle caused by a defective oxoglutarate dehydrogenase complex (OGDC). OGDC catalyzes the conversion of 2-ketoglutarate into succinyl-CoA. This disorder is characterized by a large accumulation of 2-ketoglutarate in the urine. Symptoms of the disorder include opisthotonus, ataxia, developmental delay, and seizures.
|
Disease
|
|
|
SMP0130707
View Pathway
|
2-mercaptobenzothiazole Drug Metabolism
2-mercaptobenzothiazole is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. 2-mercaptobenzothiazole passes through the liver and is then excreted from the body mainly through the kidney.
|
Metabolic
|
|
|